GENESIS Pharma and Deciphera Pharmaceuticals announce an exclusive distribution agreement for RIPRETINIB in 14 European markets in Central and Eastern Europe. Under the terms of the agreement, GENESIS Pharma will exclusively commercialize RIPRETINIB for the treatment of fourth-line gastrointestinal stromal tumor in: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia, and Slovenia. RIPRETINIB is approved in the European Union for the treatment of adult patients with advanced gastrointestinal stromal tumour who have received prior treatment with three or more kinase inhibitors, including imatinib.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DCPH: